{"name":"Arcus Biosciences","slug":"arcus","ticker":"RCUS","exchange":"NASDAQ","domain":"arcusbio.com","description":"Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating ","hq":"Hayward, CA","founded":0,"employees":"601","ceo":"Terry Rosen","sector":"Immuno-Oncology","stockPrice":24.95,"stockChange":-0.05,"stockChangePercent":-0.2,"marketCap":"$3.1B","metrics":{"revenue":247000000,"revenueGrowth":-39.3,"grossMargin":-121.6,"rdSpend":523000000,"netIncome":-353000000,"cash":822000000,"dividendYield":0,"peRatio":-7.9,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"DURVa patent cliff ($0.0B at risk)","drug":"DURVa","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"DURVa (combination) patent cliff ($0.0B at risk)","drug":"DURVa (combination)","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"AB308","genericName":"AB308","slug":"ab308","indication":"Other","status":"phase_1"},{"name":"AB598","genericName":"AB598","slug":"ab598","indication":"Other","status":"phase_1"},{"name":"AB680","genericName":"AB680","slug":"ab680","indication":"Other","status":"phase_1"},{"name":"AB801","genericName":"AB801","slug":"ab801","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"IPI-549","genericName":"IPI-549","slug":"ipi-549","indication":"Solid tumors","status":"phase_2"},{"name":"SG","genericName":"SG","slug":"sg","indication":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)","status":"marketed"}]}],"pipeline":[{"name":"AB308","genericName":"AB308","slug":"ab308","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IPI-549","genericName":"IPI-549","slug":"ipi-549","phase":"phase_2","mechanism":"PI3K/mTOR inhibitor","indications":["Solid tumors","Non-small cell lung cancer"],"catalyst":""},{"name":"SG","genericName":"SG","slug":"sg","phase":"marketed","mechanism":"SG is an adenosine 2A receptor antagonist that blocks immunosuppressive signaling in the tumor microenvironment to enhance anti-tumor immunity.","indications":["Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"],"catalyst":""},{"name":"AB598","genericName":"AB598","slug":"ab598","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AB680","genericName":"AB680","slug":"ab680","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AB801","genericName":"AB801","slug":"ab801","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Arcus Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Arcus Biosciences reported its fourth quarter and full year 2023 financial results, highlighting a net loss of $44.6 million and a cash balance of $234.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-18","type":"deal","headline":"Arcus Biosciences Announces Collaboration with Merck to Develop Novel Cancer Therapies","summary":"Arcus Biosciences announced a collaboration with Merck to develop novel cancer therapies, expanding its pipeline and increasing its chances of success.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"trial","headline":"Arcus Biosciences Announces Positive Interim Results from Phase 1/2 Clinical Trial of DURVa","summary":"Arcus Biosciences announced positive interim results from its Phase 1/2 clinical trial of DURVa, a novel cancer therapy.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOdDU4bTd0VHE1VWlQYmlucWVJd3RxT0lucHQta0t3UjZRRlJkS2tlV0lqaGVqdTFpQko1cGNDdlZSak5qd1U0b21VdXRXRnlPLVJDanppR2VsVFpuZGhTVm5HSzZFaUpBaVRDN1NBSnpKdDl5cDFNdDhQTlNZSDlRQ3BTdHl1Y3pTRXRrcmJEdUlVQjEwd2hGQi1fbHhNR2dLZEthaURRdmxsX1h2?oc=5","date":"2026-04-01","type":"pipeline","source":"24/7 Wall St.","summary":"5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up - 24/7 Wall St.","headline":"5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up - 24/7 Wall St.","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-11","type":"trial","source":"simplywall.st","summary":"Why Arcus Biosciences (RCUS) Is Up 9.5% After New Casdatifan Data And Pipeline Expansion - simplywall.st","headline":"Why Arcus Biosciences (RCUS) Is Up 9.5% After New Casdatifan Data And Pipeline Expansion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQdldsellnNVdxcnV3WHhTUVNidzZBZ3dBVGlwWTZzdWs3djVvbkEyMVJaNC1ydDBKazFHdHg3cEpwS0wyVkJBajZrdVJiTkhFOFQwd0lESzV3dEZrYTdSdUVSbTZBcERMbm5NLTl4MkNYTkhiWHZPbGdvY2l4b1hIREpUbTNjeUpnWFhlUFRjbE1VQXVOMjRNa3NNTEpvYXpTVWtraG9qdzlhal9TZmsxVWFB?oc=5","date":"2026-02-27","type":"earnings","source":"TradingView","summary":"RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus - TradingView","headline":"RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-26","type":"pipeline","source":"simplywall.st","summary":"Is Arcus Biosciences (RCUS) Pricing Reflect Its 1‑Year Surge And Mixed Valuation Signals - simplywall.st","headline":"Is Arcus Biosciences (RCUS) Pricing Reflect Its 1‑Year Surge And Mixed Valuation Signals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNMlVMWlBQTmZ4SzQ4TnNIQnVQQjI2QmJXblNuWnZxVndTekhGR0xWc2VaWFFoRFNhbm5MdTluTGFHcWFlUUxWMGdnS01TMmdfWW50SkNVUkcyNGZJcTZ0M2NPbkVUWWdkRjZWOXFWcy1lMnpUdUpPVDZKbkw3MVNrQllxaDg2cjRQM0N0NjFpM0d0YXMwQ1E0?oc=5","date":"2026-02-26","type":"earnings","source":"Finviz","summary":"Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues - Finviz","headline":"Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues","sentiment":"neutral"},{"date":"2026-02-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPclYwQzlFeklzaEJlWmpEd043aEExZFh3MVprVDZMZ1AyMDA0U19Dc2lMRk5pckt5TlFrTVhMaDBjRmJPdktubmR4TlR3ZHdoMURLTDZYaEcwOUxVd0xGLW94ZGp3dFRDamFQMUtsWVExbXFxUElQZVF2UklLc0lONWpZek02aEJ0NUk2eWJENmYyR2JWUTdUWGtVa29ZdER5TThpbXdSbm9yb2laZUdFVlRKRWtHd1VIQ2I1N3RBT2FPTW8?oc=5","date":"2026-01-08","type":"pipeline","source":"TechStock²","summary":"Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens - TechStock²","headline":"Arcus Biosciences (NYSE:RCUS) stock slides on Morgan Stanley downgrade as casdatifan 2026 timeline sharpens - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQYXhzSWJ0T3hBOW5nTTZtVTAxZTRha2t5UmhEZEZ6SmNOdVlUMjVOWW1OOHpsX3hRT1RCemNEUVRacWcyamJmaXp5dVFSU2VnWllpZ0o4SURpM0dFUHdtMm5ibVhNdGtrdGJlZEtrekU5X0dKMktRVmhZQVVjaUY1T2lqdGt1Z3JOZmFkd0s2OHBEbmpJdTdsUzJndm5TYVBfSzBZTVU0SHpOLXRPRGJxMXpaSWN6NTVwMUR5TkI0eDM2alE?oc=5","date":"2025-12-12","type":"trial","source":"Reuters","summary":"Arcus scraps late-stage cancer trial after weak survival data - Reuters","headline":"Arcus scraps late-stage cancer trial after weak survival data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNeVdSZ18yTV9qN05JZEl3dW9Nd092TDNSbk1NODBFcUJDV3BfQUxmTkYzaFNmai01RkYtSVJyODhJYmZIU1FBc2JhQmxkMlJ3bFZ0Q05keE9wal92aVZBU09uODFmWURKZFlfbktwSHR4blVTQV93TUg5VDk3ZXNybE1n?oc=5","date":"2025-10-07","type":"pipeline","source":"Yahoo Finance","summary":"Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock? - Yahoo Finance","headline":"Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQYUV2TlR2SkV1QmJ0OXVBQ1VVTGJZbE1qelMyRVRLS00wQnhBYUxTZFJuSlF6Zkt5a3M3RTBjeEFBZHI4UzVVZXp1YmdVUllUakxseWVyVmdyaGNXQUs3VTE4ZEdaU0pfeTV3cE9sQXVjRlQxRFY3cFFIM1lmemtYcnVEa0N5YUN3VFZ6SURyeHRSbEU3YVA4MkhwTldNVjRpQ0V2Wld0M00teFpvSUE?oc=5","date":"2025-08-10","type":"deal","source":"Seeking Alpha","summary":"Arcus Biosciences - A Risky Buy Ahead Of Pivotal, Catalyst Rich 12 Months (NYSE:RCUS) - Seeking Alpha","headline":"Arcus Biosciences - A Risky Buy Ahead Of Pivotal, Catalyst Rich 12 Months (NYSE:RCUS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE9RS253ZURyWGZhZEF6WHo4Z3NtcTFGa05mTzlZS0FmLWlGOXB2WmdQNDM3Ym1ubEV5X1ZMVGpqNHg0bzFNamFpc2VmR0ZhR1R5ZTBsTTNUSjNCWFppNXQ5X2lxcFNtNzZsdHoxQ3dFQW5EN2pC?oc=5","date":"2025-06-02","type":"trial","source":"The Pharma Letter","summary":"Arcus unveils kidney cancer data as it eyes Phase III challenge to Merck’s Welireg - The Pharma Letter","headline":"Arcus unveils kidney cancer data as it eyes Phase III challenge to Merck’s Welireg","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE5UMGd6S0phYlE3bkI5S0NHYThxQjNvYzROUTZOUzJPN1dIQVVSVTVDT3RNSHBON000NnUxWHJxZ21GVjlhWDBlV3JXdC1xLVRE?oc=5","date":"2024-02-05","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNTWdVOWRXTWVUSlYwQjNSbzQ3RjFzUFJGMk9kWkZHaEhsMUREdEdtWmZBWHl5UDM0U2dwUmczUjFkTkM4LWNXMFhzck54M2FTYWlIQXFNZjh0dlhOQUdLY2JnTFJ3U3NQN3JGc1hBWGxJbjl0NV9kVWZrclRIWTR2dHVR?oc=5","date":"2023-07-12","type":"pipeline","source":"Barron's","summary":"Gilead Just Bought $30 Million More of 2 Biotech Stocks - Barron's","headline":"Gilead Just Bought $30 Million More of 2 Biotech Stocks - Barron's","sentiment":"neutral"}],"patents":[{"drugName":"DURVa","drugSlug":"durvalumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"DURVa (combination)","drugSlug":"durvalumab-(combination)","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":6,"phaseCounts":{"phase_1":4,"phase_2":1,"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","AstraZeneca"],"therapeuticFocus":["Immuno-Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":247000000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":247000000,"period":"2025-12-31"},{"value":258000000,"period":"2024-12-31"},{"value":258000000,"period":"2024-12-31"},{"value":117000000,"period":"2023-12-31"},{"value":117000000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":523000000,"rdSpendHistory":[{"period":"2025-12-31","value":523000000},{"period":"2024-12-31","value":448000000},{"period":"2023-12-31","value":340000000},{"period":"2022-12-31","value":288000000}],"sgaSpend":110000000,"operatingIncome":-386000000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-386000000},{"period":"2024-12-31","value":-310000000},{"period":"2023-12-31","value":-340000000},{"period":"2022-12-31","value":-280000000}],"netIncome":-353000000,"netIncomeHistory":[{"period":"2025-12-31","value":-353000000},{"period":"2024-12-31","value":-283000000},{"period":"2023-12-31","value":-307000000},{"period":"2022-12-31","value":-267000000}],"eps":-3.14,"epsHistory":[{"period":"2024-12-31","value":-3.14},{"period":"2023-12-31","value":-4.15},{"period":"2022-12-31","value":-3.71},{"period":"2021-12-31","value":0.71}],"cash":222000000,"cashHistory":[{"period":"2025-12-31","value":222000000},{"period":"2024-12-31","value":150000000},{"period":"2023-12-31","value":127000000},{"period":"2022-12-31","value":206000000}],"totalAssets":1139000000,"totalLiabilities":508000000,"totalDebt":112000000,"equity":631000000,"operatingCashflow":-482000000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-482000000},{"period":"2024-12-31","value":-170000000},{"period":"2023-12-31","value":-306000000},{"period":"2022-12-31","value":438000000}],"capex":-2000000,"capexHistory":[{"period":"2025-12-31","value":-2000000},{"period":"2024-12-31","value":-6000000},{"period":"2023-12-31","value":-24000000},{"period":"2022-12-31","value":-6000000}],"freeCashflow":-484000000,"dividendsPaid":null,"buybacks":-6000,"employees":601,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":26000000,"ebit":-104000000,"ebitda":-101000000,"period":"2025-12-31","revenue":33000000,"epsBasic":-0.89,"netIncome":-106000000,"rdExpense":121000000,"epsDiluted":-0.89,"grossProfit":null,"operatingIncome":-114000000},{"sga":27000000,"ebit":-132000000,"ebitda":-130000000,"period":"2025-09-30","revenue":26000000,"epsBasic":-1.27,"netIncome":-135000000,"rdExpense":141000000,"epsDiluted":-1.27,"grossProfit":null,"operatingIncome":-142000000},{"sga":29000000,"ebit":2000000,"ebitda":4000000,"period":"2025-06-30","revenue":160000000,"epsBasic":0,"netIncome":0,"rdExpense":139000000,"epsDiluted":0,"grossProfit":null,"operatingIncome":-8000000},{"sga":28000000,"ebit":-111000000,"ebitda":-108000000,"period":"2025-03-31","revenue":28000000,"epsBasic":-1.14,"netIncome":-112000000,"rdExpense":122000000,"epsDiluted":-1.14,"grossProfit":null,"operatingIncome":-122000000},{"sga":28000000,"ebit":-92000000,"ebitda":-89000000,"period":"2024-12-31","revenue":26000000,"epsBasic":-1.03,"netIncome":-94000000,"rdExpense":101000000,"epsDiluted":-1.03,"grossProfit":null,"operatingIncome":-103000000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":24.95,"previousClose":25,"fiftyTwoWeekHigh":28.72,"fiftyTwoWeekLow":7.91,"fiftyTwoWeekRange":"7.91 - 28.72","fiftyDayAverage":23.38,"twoHundredDayAverage":19.2,"beta":0.87,"enterpriseValue":2435329024,"forwardPE":-7.9,"priceToBook":5.98,"priceToSales":13.3,"enterpriseToRevenue":10.32,"enterpriseToEbitda":-6.26,"pegRatio":0,"ebitda":-389000000,"ebitdaMargin":-164.8,"freeCashflow":-156000000,"operatingCashflow":-488000000,"totalDebt":113000000,"debtToEquity":21.6,"currentRatio":4.04,"returnOnAssets":-23.1,"returnOnEquity":-70,"analystRating":"1.5 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":11,"targetMeanPrice":34.18,"targetHighPrice":47,"targetLowPrice":20,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":29.1,"institutionHeldPercent":75.6,"sharesOutstanding":125773162,"floatShares":89076327,"sharesShort":10877577,"shortRatio":8.44,"shortPercentOfFloat":8.6,"epsTrailing":-3.17,"epsForward":-3.17,"revenuePerShare":2.07,"bookValue":4.17,"officers":[{"age":65,"name":"Dr. Terry J. Rosen Ph.D.","title":"Co-Founder, Chairman & CEO"},{"age":67,"name":"Dr. Juan Carlos Jaen Ph.D.","title":"Co- Founder & President"},{"age":52,"name":"Mr. Robert C. Goeltz II","title":"Principal Financial Officer & CFO"},{"age":54,"name":"Ms. Jennifer A. Jarrett M.B.A.","title":"Advisor"},{"age":null,"name":"Dr. Richard A. Markus M.D., Ph.D.","title":"Chief Medical Officer"},{"age":null,"name":"Dr. K. Christopher  Garcia Ph.D.","title":"Co-Founder & Member of Scientific Advisory Board"},{"age":49,"name":"Mr. Alexander  Azoy CPA","title":"Chief Accounting Officer"},{"age":56,"name":"Dr. Jonathan  Yingling Ph.D.","title":"Chief Scientific Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://arcusbio.com","phone":"510 694 6200"}}